Skip to main content
Premium Trial:

Request an Annual Quote

ABI Reports Increased Revenues, Decreased Earnings in Q4

This article has been updated from a previous version, with additional information about the difference between ABI's 2004 and 2003 Q4 revenues.

 

NEW YORK, July 28 (GenomeWeb News) - Applied Biosystems today reported a significant drop in earnings amid increasing revenues for the fourth quarter of fiscal 2004.

 

ABI said that its net earnings for Q4 2004 were $51.1 million, or $.20 per share, versus $96.1 million, or $.46 per share in Q4 2003. The company said that the Q3 earnings included special items that increased net income by $47.9 million, including: a $27.8-million benefit for reduction of valuation allowances on deferred tax assets resulting from the expected utilization of foreign tax credits and a reduction of the income tax liability due to the settlement of overseas tax audits; a $16.4-million gain resulting from completing a patent-infringement lawsuit; and a benefit of $3.7 million stemming from a reduction in previously recorded severance costs. Net income for the entire fiscal 2004 was $182.9 million, a slight dip from the $183.2 million reported for fiscal 2003.

 

Net revenues in the fourth quarter were $460.5 million, a six-percent increase over the $432.9 million reported in the same period last year. ABI said that Q4 2004 instrument revenues increased seven percent, to $231.2 million, and consumables revenues increased three percent to $153 million. In addition, revenues from other sources, such as service and support, royalties, licenses, and consulting increased 12 percent to $76.3 million.

 

R&D spending took a light hit, falling to $56.4 million in Q4 2004 from $58.2 million for the same quarter last year.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.